<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02804828</url>
  </required_header>
  <id_info>
    <org_study_id>GW140146</org_study_id>
    <nct_id>NCT02804828</nct_id>
  </id_info>
  <brief_title>Mitochondrial Cocktail for Gulf War Illness</brief_title>
  <official_title>Beyond Benefits of Q10: Mitochondrial Cocktail for Gulf War Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop preliminary evidence, such as effect size and&#xD;
      variance estimates, to guide successful conduct of a properly-powered clinical trial to&#xD;
      assess the benefit of a mitochondrial cocktail (incorporating individualization of treatment)&#xD;
      in Gulf War illness (GWI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Design study is followed by Crossover to open label treatment.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in single item General Self-Rated Health Visual Analog Scale from baseline</measure>
    <time_frame>0, 3, 6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent improved on Gulf War Illness Modified Lower Extremity Performance Score/timed chair rises</measure>
    <time_frame>6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of symptoms (out of 20 on the UCSD Symptom Score Survey) showing more favorable change (trend or effect) on active treatment vs. placebo</measure>
    <time_frame>0, 3, 6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change of CoQ10 and Vitamin E levels, comparing active treatment to placebo</measure>
    <time_frame>6 months (double-blind phase)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of summed symptom score (sum of ratings for UCSD GWI symptom index)</measure>
    <time_frame>6, 9, 12 months</time_frame>
    <description>Secondary measures will incorporate assessment of summed symptom score (sum of ratings for UCSD GWI symptom index) at primary endpoint time point. We will assess at additional time points (9, 12 month) and will assess effects stratified by sex; by dominant ethnicity; and by use of medications that can affect levels or disposition of supplement components (e.g. statin use).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Gulf War Syndrome</condition>
  <condition>Persian Gulf Syndrome</condition>
  <condition>Mitochondrial Disorders</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Individualized mitochondrial cocktail</intervention_name>
    <description>Nutrient cocktail comprising: thiamine, nicotinamide, pantothenic acid, riboflavin, L-carnitine, alpha lipoic acid, CoQ10, vitamin C, vitamin E, and omega 3 fatty acids (Cod Liver Oil).</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 months for the double-blind phase</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet symptom criteria for Gulf War illness with BOTH the Centers for Disease Control&#xD;
             and Prevention (CDC) Criteria (persistent symptoms in at least 2 of 3 designated&#xD;
             symptom domains of fatigue/sleep, mood/cognition, and musculoskeletal) and Kansas&#xD;
             Criteria (score a moderate or severe rating in at least 3 of the 6 symptom domains of&#xD;
             fatigue, pain, neurological/cognitive/mood, skin, GI and respiratory).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have conditions like multiple sclerosis or lupus that can produce similar symptoms and&#xD;
             be confused for Gulf War illness.&#xD;
&#xD;
          -  Participating in a concurrent treatment trial.&#xD;
&#xD;
          -  Unwilling or unable to comply with the treatment protocol&#xD;
&#xD;
          -  Failed run-in; do not take at least 80% of run-in medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Beatrice Golomb</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Persian Gulf Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

